Zucara is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with insulin dependent diabetes. This pre-clinical technology is directed at regulating somatostatin in the pancreas which in Type 1 diabetes is not properly controlled. Our novel somatostatin receptor antagonist has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
A robust preclinical data package has been generated with a prototype cyclic peptide compound, PRL-2903. In vivo efficacy has been confirmed through independent validation studies and ADME/T screening has been completed to select a lead drug candidate, ZT-01, for continued development.